Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05764395
Title Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.